Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 75

Sort by

Sort Order Select

Journal Articles

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Krauss, Arend von Stackelberg, Semjon Willier, Christina Peters, Tobias Feuchtinger

Blood (2023) 142 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2023-190117

Published: 2023

Journal Articles

Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials

Anita Lawitschka, Jean-Hugues Dalle, Ulrike Pötschger, Helga Arnardottir, Petr Sedlacek, Jochen Büchner, Marianne Ifversen, Peter Svec, Jerry Stein, Tayfun Güngör, Jacek Toporski, Cristina Díaz De Heredia, Marc Bierings, Roland Meisel, Marc Ansari, Adriana Balduzzi, Franco Locatelli, Christina Peters, Peter Bader

Blood (2023) 142 (Supplement 1): 110.

https://doi.org/10.1182/blood-2023-186850

Published: 2023

Journal Articles

Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study

Blood (2023) 142 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2023-187587

Published: 2023

Journal Articles

Relapse Is the Most Common Treatment Failure Post HSCT in Children with ALL below 4 Years of Age Given a Chemo-Based Conditioning Regimen. Results from the Prospective Multinational Forum-Trial

Christina Peters, Ulrike Poetschger, Jean-Hugues Dalle, Akif Yesilipek, Jerry Stein, Herbert Pichler, Adriana Balduzzi, Franco Locatelli, Petr Sedlacek, Jacek Wachowiak, Tayfun Güngör, Marianne Ifversen, Marleen Renard, Tony H Truong, Raquel Staciuk, Peter J. Shaw, Gergely Kriván, Jochen Büchner, Peter Bader

Blood (2022) 140 (Supplement 1): 897–899.

https://doi.org/10.1182/blood-2022-168609

Published: 2022

Journal Articles

Long-Term Data Confirm the Superiority of Total Body Irradiation-Containing Conditioning Regimen in Comparison to a Chemotherapy-Based Preparation in Children with Acute Lymphoblastic Leukemia Above the Age of 4 Years Given an Unmanipulated Allograft. Results of the Forum Randomized Clinical Trial

Franco Locatelli, Peter Bader, Jean-Hugues Dalle, Ulrike Poetschger, Herbert Pichler, Petr Sedlacek, Jochen Büchner, Peter J. Shaw, Marianne Ifversen, Raquel Staciuk, Kim Vettenranta, Adriana Balduzzi, Christina Peters

Blood (2022) 140 (Supplement 1): 4865–4867.

https://doi.org/10.1182/blood-2022-166048

Published: 2022

Journal Articles

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Jakob D. Rudzki, Ulrich Jaeger, Dominik Wolf, Andreas Petzer, Richard Greil, Christina Peters, Hildegard T. Greinix, Andishe Attarbaschi, Veronika Buxhofer-Ausch, Michael Girschikofsky, Wolfgang Holter, Michael Leisch, Peter Neumeister, Peter Schlenke, Clemens A. Schmitt, Wolfgang Schwinger, Nina Worel, Philipp Wohlfarth

Blood (2022) 140 (Supplement 1): 6661–6663.

https://doi.org/10.1182/blood-2022-167603

Published: 2022

Journal Articles

Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study

Jean-Hugues Dalle, Peter Bader, Akif Yesilipek, Franco Locatelli, Julia Palma, Jacek Wachowiak, Herbert Pichler, Marianne Ifversen, Gergely Kriván, Jochen Buechner, Cristina Díaz-de-Heredia, Marc Bierings, Raquel Staciuk, Tayfun Gungor, Jacek Toporski, Adriana Balduzzi, Ulrike Poetschger, Christina Peters, Petr Sedlacek

Blood (2022) 140 (Supplement 1): 903–905.

https://doi.org/10.1182/blood-2022-164735

Published: 2022

Journal Articles

Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)

Blood (2021) 138 (Supplement 1): 1231.

https://doi.org/10.1182/blood-2021-145476

Published: 2021

Journal Articles

Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study

Blood (2021) 138 (Supplement 1): 2862.

https://doi.org/10.1182/blood-2021-145858

Published: 2021

Journal Articles

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Blood (2018) 132 (Supplement 1): 655.

https://doi.org/10.1182/blood-2018-99-112854

Published: 2018

Journal Articles

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

Blood (2018) 132 (Supplement 1): 895.

https://doi.org/10.1182/blood-2018-99-112599

Published: 2018

Journal Articles

AML SCT-BFM 2007: Results of the Prospective Hematopoietic Stem Cell Transplantation (HCT) Trial of the Berlin-Frankfurt-MÃ¼nster (BFM) Study Group for Children with Very High Risk Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 599.

https://doi.org/10.1182/blood.V130.Suppl_1.599.599

Published: 2017

Journal Articles

Osteonecrosis after Allogeneic HSCT in Children with High-Risk or Relapsed ALL Treated in the ALL-SCT 2003 Trial

Michaela Kuhlen, MD, Michael H. Albert, Peter Bader, MD PhD, Karoline Ehlert, MD, Tayfun Guengoer, Thomas Klingebiel, MD, Peter J. Lang, MD, Martin Schrappe, MD PhD, Johanna Schrum, MD, Ansgar S. Schulz, MD, Arend von Stackelberg, MD, Brigitte Strahm, PD Dr., Karl-Walter Sykora, MD, Irene Teichert-von Luettichau, MD, Arndt Borkhardt, Prof MD, Roland Meisel, MD, Ulrike Poetschger, Evgenia Glogova, Christina Peters, MD

Blood (2017) 130 (Supplement 1): 2004.

https://doi.org/10.1182/blood.V130.Suppl_1.2004.2004

Published: 2017

Journal Articles

Outcome of Children Developing Grade III-IV Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Report on Behalf of the EBMT Paediatric Diseases Working Party

Alice Bertaina, MD PhD, Franco Locatelli, MD PhD, Anita Lawitschka, Adriana Balduzzi, MD, Jean-Hugues Dalle, MD PhD, Petr Sedlacek, MD, Andre Manfred Willasch, MD, Isaac Yaniv, MD, Christina Peters, MD, Peter Bader, MD PhD

Blood (2017) 130 (Supplement 1): 76.

https://doi.org/10.1182/blood.V130.Suppl_1.76.76

Published: 2017

Journal Articles

Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study

Andre Manfred Willasch, MD, Christina Peters, MD, Petr Sedlacek, MD, Jean-Hugues Dalle, MD, Stelios Graphakos, MD, Akif Yesilipek, MD, Jacek Wachowiak, Prof MDPhD, Arjan Lankester, MD PhD, Arcangelo Prete, MD, Amir Ali Hamidieh, MD, Marianne Ifversen, Jochen Büchner, MDPhD, Gergely Krivan, MD, Rose-Marie Hamladji, MD, Cristina Diaz de Heredia, MD, Elena Skorobogatova, MD PhD, Gerard Michel, MD, Franco Locatelli, MD PhD, Alice Bertaina, MD PhD, Paul Veys, MD, Sophie Dupont, MD, Reuven Or, MD, Tayfun Guengoer, Olga Aleinikova, MD PhD, Sabina Sufliarska, MD, Mikael Sundin, MD PhD, Jelena Rascon, MD, Ain Kaare, MD, Damir Nemet, MD PhD, Franca Fagioli, MD, Thomas Klingebiel, MD, Jan Styczynski, PhD, Marc B Bierings, MDPhD, Kalman Nagy, MD, Manuel Abecasis, MD, Boris V Afanasyev, MD PhD Professor, Marc Ansari, MD, Arnaud Dalissier, Myriam Labopin, MD, Eric Beohou, Peter Bader, MD PhD

Blood (2017) 130 (Supplement 1): 911.

https://doi.org/10.1182/blood.V130.Suppl_1.911.911

Published: 2017

Journal Articles

Second Allogeneic Hematopoietic Stem Cell Transplantation for Post-Transplant Relapsed Acute Leukemia in Children - an EBMT PDWP Retrospective Study

Isaac Yaniv, MD, Aviva C. Krauss, MD, Eric Beohou, Arnaud Dalissier, Selim Corbacioglu, MD PhD, Marco Zecca, MD, Boris V Afanasyev, MD PhD Professor, Massimo Berger, MD, Miguel Angel Diaz, MD, Krzysztof Kalwak, MD, Petr Sedlacek, MD, Stefania Varotto, MD, Christina Peters, MD, Peter Bader, MD PhD

Blood (2017) 130 (Supplement 1): 912.

https://doi.org/10.1182/blood.V130.Suppl_1.912.912

Published: 2017

Journal Articles

A Protective Role of DNA Repair Genes Against Acute Graft Versus Host Disease in Children

Patricia Huezo-Diaz, Chakradhara RS Uppugunduri, PhD, Mohamed Aziz Rezgui, MsC, Anuj Tyagi, PhD, Vid Mlakar, PhD, Laurence Lesne, MSc, Tiago Nava, MD, Yves Theoret, PhD, Yves Chalandon, MD PhD, Robbert Bredius, PhD MD, Jean-Hugues Dalle, MD PhD, Peter Bader, MD PhD, Christina Peters, MD, Henrique Bittencourt, MD PhD, Maja Krajinovic, MD PhD, Marc Ansari, MD

Blood (2017) 130 (Supplement 1): 749.

https://doi.org/10.1182/blood.V130.Suppl_1.749.749

Published: 2017

Journal Articles

Outcome of Children Relapsing after First Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia: A Retrospective I-BFM Analysis of 336 Children between 2005 and 2016

Blood (2017) 130 (Supplement 1): 272.

https://doi.org/10.1182/blood.V130.Suppl_1.272.272

Published: 2017

Journal Articles

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation

Jessica I Hoell, MD, Sebastian Ginzel, MSc, Cornelia Eckert, PhD, Michael Gombert, PhD, Ute Fischer, PhD, Martin Stanulla, MD, Martin Schrappe, MD PhD, Udo zur Stadt, PhD, Peter Bader, MD, Brigitte Strahm, MD, Julia Alten, Anja Moericke, MD, Gabriele Escherich, MD, Arend Stackelberg, MD, Christina Peters, MD, Arndt Borkhardt, MD, Roland Meisel, MD

Blood (2016) 128 (22): 601.

https://doi.org/10.1182/blood.V128.22.601.601

Published: 2016

Journal Articles

Contemporary Conditioning Regimen before Allogeneic Stem Cell Transplantation for Children with Non-Malignant Diseases

Christina Peters, MD, Mary Slatter, MD, Paul Veys, MD Prof., Franco Locatelli, MD, Adriana Balduzzi, MD, M. Akif Yesilipek, Prof. Dr., Jean-Hugues Dalle, MD PhD Prof., Marina Cavazzana, MD PhD, Jaap Jan Boelens, MD PhD, Isaac Yaniv, MD Prof., Ansgar S Schulz, MD PhD Prof., Jacek Wachowiak, Prof MD PhD, Manfred Hoenig, MD, Arjan C Lankester, MD PhD, Benedicte Neven, MD PhD, Eric Beohou, Arnaud Dallisier, Peter Bader, MD, Andrew Gennery, MD

Blood (2016) 128 (22): 3398.

https://doi.org/10.1182/blood.V128.22.3398.3398

Published: 2016

NARROW

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials

Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study

Relapse Is the Most Common Treatment Failure Post HSCT in Children with ALL below 4 Years of Age Given a Chemo-Based Conditioning Regimen. Results from the Prospective Multinational Forum-Trial

Long-Term Data Confirm the Superiority of Total Body Irradiation-Containing Conditioning Regimen in Comparison to a Chemotherapy-Based Preparation in Children with Acute Lymphoblastic Leukemia Above the Age of 4 Years Given an Unmanipulated Allograft. Results of the Forum Randomized Clinical Trial

Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL - First Data from the Austrian CAR-T Network

Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study

Superior Overall Survival with Blinatumomab Versus Chemotherapy As Pre-Transplant Consolidation Treatment in Children with High-Risk First-Relapse B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL): Longer Follow-up (FU) of a Phase 3 Randomized Controlled Trial (RCT)

Outcome of Allogeneic HSCT after Chemo-Based Conditioning in Infants with Acute Myeloid Leukemia in First Complete Remission: A Multicenter EBMT-PDWP Study

Outcome of Infants Younger Than 1 Year with Acute Lymphoblastic Leukemia Treated with the Interfant-06 Protocol; Results from an International Randomised Study

Updated Analysis of the Efficacy and Safety of Tisagenlecleucel in Pediatric and Young Adult Patients with Relapsed/Refractory (r/r) Acute Lymphoblastic Leukemia

AML SCT-BFM 2007: Results of the Prospective Hematopoietic Stem Cell Transplantation (HCT) Trial of the Berlin-Frankfurt-MÃ¼nster (BFM) Study Group for Children with Very High Risk Acute Myeloid Leukemia

Osteonecrosis after Allogeneic HSCT in Children with High-Risk or Relapsed ALL Treated in the ALL-SCT 2003 Trial

Outcome of Children Developing Grade III-IV Acute Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation: A Report on Behalf of the EBMT Paediatric Diseases Working Party

Myeloablative Conditioning for First Allogeneic Hematopoietic Stem Cell Transplantation in Children with ALL: Total Body Irradiation or Chemotherapy? - a Multicenter EBMT-PDWP Study

Second Allogeneic Hematopoietic Stem Cell Transplantation for Post-Transplant Relapsed Acute Leukemia in Children - an EBMT PDWP Retrospective Study

A Protective Role of DNA Repair Genes Against Acute Graft Versus Host Disease in Children

Outcome of Children Relapsing after First Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Myeloid Leukemia: A Retrospective I-BFM Analysis of 336 Children between 2005 and 2016

Mutational Landscape of Pediatric Acute Lymphoblastic Leukemia Relapsing after Allogeneic Stem Cell Transplantation

Contemporary Conditioning Regimen before Allogeneic Stem Cell Transplantation for Children with Non-Malignant Diseases

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only